title: [Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases].
abstract: We evaluated efficacy and safety of monotherapy with CZOP (1-2 g x 2/day) and combination therapy with CZOP (1-2 g x 2/day) and AMK (200 mg x 2/day) for infections in patients with hematological diseases. Efficacy was evaluated in 71 patients of monotherapy group and 70 patients of combination therapy group. Underlying diseases were mostly leukemia and lymphoma. Infections included sepsis, suspected sepsis, pneumonia and so on. Efficacy in CZOP monotherapy was excellent in 21 patients (31.3%), good in 23 patients (34.3%), fair in 5 patients (7.5%) and the efficacy rate was 65.7%. On the other hand, in combination therapy, each was 14 patients (21.2%), 23 patients (34.8%), 12 patients (18.2%) and the efficacy rate was 56.1%. Side effects such as eruption were noted in 2 patients. Abnormal laboratory findings were noted in 9 patients. All side effects as well as abnormal laboratory findings were minimal. It was concluded that CZOP monotherapy was effective in the treatment of various infections accompanying hematological diseases.
authors.affiliation: Division of Hematology, NTT Kanto Medical Center.
authors.forename: A
authors.initials: A
authors.lastname: Urabe
authors.forename: A
authors.initials: A
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Aoki
authors.forename: M
authors.initials: M
authors.lastname: Koike
authors.forename: K
authors.initials: K
authors.lastname: Kitamura
authors.forename: Y
authors.initials: Y
authors.lastname: Ohbayashi
authors.forename: K
authors.initials: K
authors.lastname: Oshimi
authors.forename: Y
authors.initials: Y
authors.lastname: Wakabayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kuraishi
authors.forename: I
authors.initials: I
authors.lastname: Kurihara
authors.forename: A
authors.initials: A
authors.lastname: Togawa
authors.forename: S
authors.initials: S
authors.lastname: Hoshino
authors.forename: K
authors.initials: K
authors.lastname: Ozawa
authors.forename: T
authors.initials: T
authors.lastname: Hotta
authors.forename: M
authors.initials: M
authors.lastname: Higashihara
authors.forename: H
authors.initials: H
authors.lastname: Nagoshi
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: M
authors.initials: M
authors.lastname: Omine
authors.forename: S
authors.initials: S
authors.lastname: Asano
authors.forename: M
authors.initials: M
authors.lastname: Nishimura
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Bessho
authors.forename: H
authors.initials: H
authors.lastname: Mizoguchi
authors.forename: S
authors.initials: S
authors.lastname: Furusawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nonaka
authors.forename: F
authors.initials: F
authors.lastname: Takaku
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002511:Cephalosporins / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000209:etiology; D018805:Sepsis / Q000188:drug therapy / Q000209:etiology; D000097586:Cefozopran
chemical_list: D000583:Amikacin; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097586:Cefozopran